Pediatric Hematology/Oncology

COVID-19

Questions discussed in this category

Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?

2 Answers available

Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

1 Answer available

Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?

2 Answers available

In a patient with a heterozygous prothrombin gene mutation who has COVID with minimal symptoms, do you recommend prophylactic and/or therapeutic anticoagulation?

1 Answer available

Do you routinely check platelet counts after COVID-19 vaccines in patients with chronic ITP?

1 Answer available

In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?

2 Answers available

Would you use autologous hematopoietic stem cells collected from a HR neuroblastoma patient found to be COVID positive after harvest?

Both the patient's nasopharyngeal swab and stem cells themselves resulted COVID positive post-harvesting.

1 Answer available

What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?

2 Answers available

How would you time COVID-19 vaccination with someone on R-CHOP chemotherapy?

1 Answer available

Do you recommend that children with sickle cell disease refrain from returning to school during the COVID-19 pandemic?

2 Answers available

How do you approach the decision of whether and when to initiate therapy in patients who remain COVID-19 positive >2 weeks after infection but are asymptomatic from the virus?

E.g. a patient with progression of their primary cancer but still is testing COVID19+ over a month after infection?

5 Answers available

Should we be utilizing prophylactic G-CSF in our patients with intermediate risk of febrile neutropenia due to the COVID-19 pandemic?

Are you placing more weight on patient risk factors such as age >65 or co-morbidities?

2 Answers available

What are best practices for pediatric hematology/oncology patient and staff precautions with the COVID-19 pandemic?

How are you changing your parent/visitor policies? Are you testing for COVID-19 in all febrile patients? Has COVID-19 changed the care settings...

1 Answer available

Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?

What if the patient has a history of confirmed COVID-19 but has since recovered?

1 Answer available

Would you stop current immunosuppressive therapy or delay starting immunosuppressive therapy in a patient with aplastic anemia who has been infected with COVID-19?

2 Answers available

Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?

3 Answers available

Are patients with bleeding disorders receiving plasma-derived products at increased risk of acquiring COVID-19?

1 Answer available

Should patients with bleeding disorders increase their home supplies of clotting factors foreseeing a possible shortage of product availability due to COVID-19?

1 Answer available

How would you manage a patient with sickle cell disease who is infected with COVID-19?

1 Answer available

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

2 Answers available

How should you manage a COVID-19 infected/suspected patient who is receiving chemotherapy and cannot interrupt or delay their cancer treatment?

2 Answers available

Can we use a linear accelerator to sterilize PPE?

5 Answers available

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?

Acknowledging that there is no time for good trials yet in this setting

1 Answer available

How should you manage a coronavirus infected/suspected patient who is receiving radiotherapy and cannot interrupt or delay their cancer treatment?

How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...

7 Answers available

Should extra precautions be taken for pediatric oncology patients in light of the recent COVID-19 outbreak?

A case report (https://www.ncbi.nlm.nih.gov/pubmed/32149486) describes severe COVID-19 infection in a pediatric oncology patient. Have you seen simil...

2 Answers available

How should you manage a pediatric oncology patient who has an ANC > 500 and a normal chest x-ray but is confirmed to be infected with COVID-19 and is immunosuppressed from chemotherapy?

Should the patient be admitted for observation which will risk exposing other immunocompromised patients to COVID-19, or should the patient be quarant...

1 Answer available

Should I wear gloves during a routine physical exam on an asymptomatic patient with no risk factors for COVID-19?

1 Answer available

Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?

1 Answer available

Papers discussed in this category

Lancet Oncol., 2020 Feb 14

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Ann. Oncol., 2020 Mar 26

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China.

Hong Kong medical journal = Xianggang yi xue za zhi, 2003-12

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

Lancet, 2020 Mar 04

Middle East respiratory syndrome.

Intensive Care Med, 2020 Mar 03

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Lancet, 2020 Jan 24

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Int J Antimicrob Agents, 2020 Feb 17

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.

Cell Res, 2020 Feb 04

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Biosci Trends, 2020 Jan 28

Drug treatment options for the 2019-new coronavirus (2019-nCoV).

Pediatrics, 2020 Mar 16

Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China.

Acta Paediatr., 2020 Mar 23

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults.

Br. J. Haematol., 2020 Apr 30

How we deal with the COVID-19 epidemic in an Italian paediatric onco-haematology clinic located in a region with a high density of cases.

Lancet Haematol, 2021 Feb 01

Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors.

Transfusion, 2020 May 27

SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission.

Vox Sang, 2020 Apr 21

Post-donation COVID-19 identification in blood donors.

Lancet, 2020 Feb 12

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.

Ann Oncol, 2021 Mar 18

Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.

Semin Hematol,

Epidemiology and risk factors for venous thrombosis.

Related Topics in Pediatric Hematology/Oncology